Lv6
2370 积分 2023-07-20 加入
Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial
1个月前
已完结
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
1个月前
已完结
Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis
2个月前
已完结
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological Analysis
2个月前
已完结
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis
2个月前
已完结
Exaggeration of PFS by blinded, independent, central review (BICR)
2个月前
已完结
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2个月前
已完结
A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials
2个月前
已完结
A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials
2个月前
已完结
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis
2个月前
已完结
皖公网安备34019202002308
